Plus   Neg

Stock Alert:Dr. Reddy's Laboratories Touches New High

Dr. Reddy's Laboratories Limited (RDY) touched a new high of $49.27 on Monday, April 13, before closing at $49.10, up 4.91%.

Monday, Dr. Reddy's launched Invista for the treatment of chronic accelerated or myeloid or lymphoid blast phase and newly diagnosed in chronic phase adult patients with Chronic Myeloid Leukemia (CML) in India.

Invista is a formulation of Dasatinib that is bio equivalent to the innovator brand. Indian Patent on Bristol-Myers-Squibb's Dasatinib was expired on April 12.

Dr.Reddy's has been ticking up from March 18, after touching 52-week low of $33.33. It has gained nearly 50% in less than a month

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Moderna said Tuesday that it has reached an agreement with the U.S. to initially supply 100 million doses of its experimental vaccine for COVID-19, mRNA-1273. The U.S. government has awarded up to $1.525 billion for the vaccine. Las Vegas, Nevada-based Mr. Wok Foods has recalled about 200,000 pounds of meat and poultry products for misbranding and undeclared allergens, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The recalled products may contain known allergens such as milk, wheat, soy, peanuts, or oysters. They may also contain MSG, sesame products, or sulfites. The U.S. Food and Drug Administration approved the first oral drug to treat patients two months of age and older with spinal muscular atrophy (SMA) that can be taken at home. Roche subsidiary Genentech's Evrysdi (risdiplam) is also the second FDA-approved drug to treat this rare and often fatal genetic disease affecting muscle strength and movement.
Follow RTT